A multi-omic investigation of keloid disease recurrence
Active Grant Awarded
- Award ID
- R56AR087418
- Recipient
-
Michigan State University UEI NH77YPDEGG84
- Awarding agency
-
National Insititue of Arthritis and Musculoskeletal and Skin Diseases
National Institutes of Health, Department of Health and Human Services
- Obligated
- $300,000
Award facts
- Assistance listing
- 93.846 Arthritis, Musculoskeletal and Skin Diseases Research
- Completion date 18% complete
- Place of performance
- East Lansing, MI 48824, USA
Award details come from USAspending.gov.
About this award
The Department of Health and Human Services' National Institutes of Health, through its National Institute of Arthritis and Musculoskeletal and Skin Diseases, awarded Michigan State University $300,000 on September 19, 2026, under Assistance Listing 93.846, Arthritis, Musculoskeletal and Skin Diseases Research. The grant funds a multiomics investigation of keloid disease recurrence, a condition the award record describes as the most significant challenge in keloid treatment after surgical resection. The work combines single cell RNA sequencing, spatial transcriptomics, and genome-wide genotyping on formalin-fixed paraffin-embedded surgical tissue from large retrospective and prospective cohorts. Its aims are to examine how changes in primary keloid tissue cellular heterogeneity affect recurrence and to identify expression quantitative trait loci within cell-type-specific expression networks linked to recurrence. The project focuses on African American patients, whom the preliminary findings in the record show to be more than 2.5 times as likely to experience recurrence after primary keloid surgery as European Americans, even after accounting for severity factors such as size and number. The award cites Notice of Special Interest NOT-AR-24-009, "Accelerating Research in Understudied Skin Types." The recipient is Michigan State University, doing business as Henry Ford Health+Michigan State University Health Sciences, and the place of performance is East Lansing, Michigan 48824. The ultimate completion date is August 31, 2027. The award is classified as a grant, and the record identifies no sub-recipients.
Description
- Abstract
- Keloid disease (KD), an excessive scaring disorder which affects millions of people with pain, itching, and decreased quality of life. Surgery is the most common first line KD treatment that can restore form and function after keloid development; however, recurrence after surgical resection remains the most significant challenge in the clinical treatment of keloids and suggests the existence of a surgically intolerant phenotype(S). Despite increasing evidence that changes in cellular heterogeneity is an important contributor to abnormal scar formation, there are no published single cell level studies of keloids that investigate their contributions to keloid recurrence, and the studies that have been conducted lack representation of the population in the united states that suffers disproportionately from keloid incidence and severity, african americans. Further, our preliminary findings indicate data african americans are more than 2.5 times more likely to experience recurrence following primary keloid surgery relative to european americans, even after accounting for keloid severity factors (EG. Size and number). Taken together, these aspects make KD is a prime candidate for study under the national institute of arthritis and musculoskeletal and skin diseases' notice of special interest (NOSI) "accelerating research in understudied skin types" (not-AR-24-009). Using large and representative retrospective and prospective cohorts with formalin fixed paraffin embedded (FFPE) surgical tissue, this proposal will use an innovative multiomics approach (single cell RNA sequencing, spatial transcriptomics, and genome-wide genotyping) to investigate the impact of changes in primary keloid tissue cellular heterogeneity on keloid recurrence and identify expression quantitative trait loci (EQTL) underlying the transcription of genes within cell type specific expression networks linked to keloid recurrence. The proposal's central hypothesis is that keloid fibroblast subtypes, in the context of immune cells and immune influencing cells, impact recurrence following initial surgery and that this information can be leveraged to identify patients who are recurrence prone and may benefit from alternative primary therapies. Using a rigorous and innovative multi-omics approach and an unprecedented FFPE KD surgical cohort, the central hypothesis will be tested through the completion of the following specific aims: aim 1: to discover and validate individual cell type-specific abundances and expression networks that impact KD recurrence. Aim 2: to identify primary keloid tissue cell-cell interactions and cellular spatial organization that influence recurrence.
Quick answers
Who received award R56AR087418?
R56AR087418 was awarded to Michigan State University by National Insititue of Arthritis and Musculoskeletal and Skin Diseases (National Institutes of Health) on September 19, 2026.
How much is award R56AR087418 worth?
$300,000 has been obligated on R56AR087418.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award